These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23345098)

  • 1. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.
    Hartman ML; Xu R; Crowe BJ; Robison LL; Erfurth EM; Kleinberg DL; Zimmermann AG; Woodmansee WW; Cutler GB; Chipman JJ; Melmed S;
    J Clin Endocrinol Metab; 2013 Mar; 98(3):980-8. PubMed ID: 23345098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
    Abs R; Bengtsson BA; Hernberg-Stâhl E; Monson JP; Tauber JP; Wilton P; Wüster C
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):703-13. PubMed ID: 10468941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms.
    Kehely A; Bates PC; Frewer P; Birkett M; Blum WF; Mamessier P; Ezzat S; Ho KK; Lombardi G; Luger A; Marek J; Russell-Jones D; Sönksen P; Attanasio AF
    J Clin Endocrinol Metab; 2002 May; 87(5):1974-9. PubMed ID: 11994327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program.
    Child CJ; Zimmermann AG; Chrousos GP; Cummings E; Deal CL; Hasegawa T; Jia N; Lawrence S; Linglart A; Loche S; Maghnie M; Pérez Sánchez J; Polak M; Predieri B; Richter-Unruh A; Rosenfeld RG; Yeste D; Yorifuji T; Blum WF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):379-389. PubMed ID: 30219920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study.
    Shimatsu A; Tai S; Imori M; Ihara K; Taketsuna M; Funai J; Tanaka T; Teramoto A; Irie M; Chihara K
    Endocr J; 2013; 60(10):1131-44. PubMed ID: 23823978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety aspects of GH replacement.
    Svensson J; Bengtsson BA
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S65-74. PubMed ID: 19684054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER.
    Sävendahl L; Polak M; Backeljauw P; Blair JC; Miller BS; Rohrer TR; Hokken-Koelega A; Pietropoli A; Kelepouris N; Ross J
    J Clin Endocrinol Metab; 2021 May; 106(6):1728-1741. PubMed ID: 33571362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects.
    Woodmansee WW; Hartman ML; Lamberts SW; Zagar AJ; Clemmons DR;
    Clin Endocrinol (Oxf); 2010 Jan; 72(1):59-69. PubMed ID: 19438908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of growth hormone treatment in pediatric patients with idiopathic short stature.
    Quigley CA; Gill AM; Crowe BJ; Robling K; Chipman JJ; Rose SR; Ross JL; Cassorla FG; Wolka AM; Wit JM; Rekers-Mombarg LT; Cutler GB
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5188-96. PubMed ID: 15899952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
    Underwood LE; Attie KM; Baptista J;
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5273-80. PubMed ID: 14602761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual igf-I responsiveness to a fixed regimen of low-dose growth hormone replacement is increased with less variability in obese compared to non-obese adults with severe growth hormone deficiency.
    Yuen KC; Cook DM; Rumbaugh EE; Cook MB; Dunger DB
    Horm Res; 2006; 65(1):6-13. PubMed ID: 16340214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults.
    Gilchrist FJ; Murray RD; Shalet SM
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):363-70. PubMed ID: 12201829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections.
    Johansson JO; Wirén L; Oscarsson J; Bengtsson BA; Johannsson G
    Growth Horm IGF Res; 2003 Dec; 13(6):306-15. PubMed ID: 14624763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children.
    Scirè G; Del Bianco C; Spadoni GL; Cianfarani S
    J Endocrinol Invest; 2008 Feb; 31(2):153-8. PubMed ID: 18362507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.
    Gómez JM; Gómez N; Fiter J; Soler J
    Horm Metab Res; 2000 Feb; 32(2):66-70. PubMed ID: 10741688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.